Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key drivers of cancer cell growth, resistance, and survival. With our core competencies in medicinal chemistry, cancer biology, and drug development, we rapidly translate our discoveries into potential treatments for patients with cancer.
Our target class- and technology platform-agnostic approach allows us the flexibility to focus on an array of relevant targets to rapidly develop a diverse portfolio of oncology drug candidates, with optimized drug properties, to address some of the most pressing areas of unmet medical need. Leveraging a comprehensive understanding of the molecular and cellular mechanisms that drive cancer cell growth and treatment resistance, we have advanced a diverse pipeline consisting of six distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders.
Our Clinical Trials
We are actively recruiting patients for clinical trials across a broad range of cancers. This important research helps support the development of medicines that have the potential to be safe and effective options for treating cancer. Your patient can play an important part in driving the future of cancer drug development and research. Find out if your patient qualifies.
The key to our success at Prelude is the team. We are a team of scientists, clinicians, and business leaders that have led the discovery, development, and commercialization of numerous oncology drugs that continue to impact the lives of patients with cancer. Guided by our passion and the principles of sound science, we have built a premier drug discovery and clinical team to collaboratively and efficiently to bring innovative medicines to patients with cancer. If you share our vision and mission, join us.